![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bayer, Atara Biotherapeutics Forge Partnership to Develop CAR T-Cell Therapies
Bayer, Atara Biotherapeutics Forge Partnership to Develop CAR T-Cell Therapies
![correct_handshake.gif](https://www.fdanews.com/ext/resources/test/Device_Images/handshake.gif?t=1576815772&width=430)
December 10, 2020
Bayer and Atara Biotherapeutics have struck a deal to develop mesothelin-directed chimeric antigen receptor (CAR) T-cell therapies for treating solid tumors, which work by targeting the tumor-associated antigen mesothelin often overexpressed in cancer cells.
Per the deal, Atara will spearhead preclinical studies for armored allogeneic T-cell immunotherapy candidate, ATA3271, while Bayer will submit the Investigational New Drug application and oversee follow-up clinical development and commercialization.
The deal also calls for Atara to continue development of candidate ATA2271, aimed at targeting high mesothelin-expressing tumors found in malignant pleural mesothelioma and nonsmall-cell lung cancer. The drug is currently being evaluated in a phase 1 study.
South San Francisco-based Atara will receive an initial $60 million from Bayer and is eligible to receive an additional $610 million and tiered royalties in milestone-based payments.
Upcoming Events
-
21Oct